Quoin Pharmaceuticals, Ltd. (QNRX) News
Follow Quoin Pharmaceuticals, Ltd. (QNRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 32 public stories across 14 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Quoin Pharmaceuticals Reports $4.9 Million Q3 Loss and Positive QRX003 Interim Data
Quoin reported a $4.9 million net loss for the third quarter of 2026, versus $3.9 million a year earlier, and $33.2 million in cash, cash equivalents and investments at September-end. It also reported statistically signi
EQUITY | Nov 06, 2026, 10:23 PM UTC
M
Quoin Pharmaceuticals Reports Third-Quarter Results and Positive QRX003 Interim Data
Quoin Pharmaceuticals reported third-quarter 2026 financial results and positive interim data from its ongoing Phase 2/3 QRX003 study in Netherton syndrome.
EQUITY | Nov 05, 2026, 01:37 PM UTC
L
Quoin Pharmaceuticals Receives EMA Orphan Drug Designation for QRX003
The EMA granted orphan drug designation to QRX003 for Peeling Skin Syndrome. Quoin plans to start its first formal clinical study before year-end.
EQUITY | Oct 14, 2026, 10:43 AM UTC
L
Quoin Wins EMA Orphan Drug Designation for QRX003
Quoin Pharmaceuticals received EMA orphan drug designation for QRX003 to treat Peeling Skin Syndrome. The company expects to start its first formal clinical trial for the condition before year-end.
REGULATION | Oct 14, 2026, 10:32 AM UTC
L
EMA Grants Orphan Drug Designation to Quoin’s QRX003
The European Medicines Agency granted orphan drug designation to QRX003 for treatment of peeling skin syndrome.
REGULATION | Oct 14, 2026, 10:30 AM UTC
L
Weekly Recap: Interim Phase 2/3 QRX003 success and Lake Street $20.00 target
Quoin Pharmaceuticals. Ltd Sponsored ADR (NASDAQ:QNRX) reported positive interim Phase 2/3 QRX003 results for Netherton syndrome and launched a private placement of up to $50M to potentially fund operations through H2 20
NEWS | Sep 28, 2026, 11:06 AM UTC
L
Quoin Pharmaceuticals Price Target Announced at $20.00/Share by Lake Street
Ratings actions from Benzinga: GMT) Quoin Pharmaceuticals Initiated at Buy by Lake StreetRatings actions from Benzinga
NEWS | Sep 23, 2026, 02:33 PM UTC
L
Quoin Pharmaceuticals gets FDA Fast Track for QRX003
Quoin Pharmaceuticals said the FDA granted Fast Track designation for QRX003 in Peeling Skin Syndrome. The company said it is preparing a Phase 2/3 study in 2H 2026.
EQUITY | Sep 22, 2026, 08:25 PM UTC
M
Quoin Pharmaceuticals gets FDA Fast Track for QRX003 in Peeling Skin Syndrome
FDA granted Fast Track Designation for QRX003 to treat Peeling Skin Syndrome. Quoin plans to start a Phase 2/3 study in 2H 2026.
REGULATION | Sep 22, 2026, 12:34 PM UTC
M
Quoin Pharmaceuticals gets FDA Fast Track for QRX003 peeling skin syndrome
Quoin Pharmaceuticals said the FDA granted Fast Track designation for QRX003 to treat Peeling Skin Syndrome. It added a second Fast Track designation for QRX003 in addition to Netherton Syndrome.
REGULATION | Sep 22, 2026, 12:33 PM UTC
L
Quoin Pharmaceuticals gets FDA rare pediatric disease designation for QRX003
Quoin Pharmaceuticals said the FDA granted Rare Pediatric Disease designation for QRX003 in Peeling Skin Syndrome. The item cites an original SEC filing and does not provide additional terms.
REGULATION | Sep 10, 2026, 08:15 PM UTC
L
Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Da
This New Video Explores the Daily Realities of Raising a Child with Netherton Syndrome, and Its Impact on the Whole FamilyASHBURN, Va., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. NASDAQ:QNRX (“Quoin” o
EQUITY | Sep 10, 2026, 12:34 PM UTC
L
QNRX - Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met
QNRX - Quoin Pharmaceuticals Releases New NETHERTON NOW Video: Aminah’s Story Featuring Laura Wright-Sexton, MD, the Physician Who First Met Her Daughter in the ICU
EQUITY | Sep 10, 2026, 12:30 PM UTC
M
Quoin Pharmaceuticals announces FDA rare pediatric designation for QRX003
QNRX correction: Quoin Pharmaceuticals said the FDA granted rare pediatric disease designation for QRX003 in peeling skin syndrome.
REGULATION | Sep 08, 2026, 06:12 PM UTC
L
QNRX gets FDA rare pediatric disease designation for QRX003
Quoin Pharmaceuticals said the FDA granted rare pediatric disease designation for QRX003 in peeling skin syndrome.
REGULATION | Sep 08, 2026, 12:31 PM UTC
L
Quoin Pharmaceuticals sets up to $50M private placement
Quoin Pharmaceuticals sets up a private placement of up to $50 million, adding registration rights and lock-ups.
EQUITY | Aug 28, 2026, 02:34 PM UTC
M
Dow gains 100 points as Chicago PMI falls in August
The Chicago Business Barometer dipped to 47.1 in August from 57.6 previously, missing market estimates of 58.3.
MACRO | Aug 28, 2026, 02:09 PM UTC
L
Quoin Pharmaceuticals announces private placement up to $50 million
Quoin Pharmaceuticals said it is pursuing a private placement financing of up to $50 million.
EQUITY | Aug 28, 2026, 12:06 PM UTC
L
Quoin Pharmaceuticals announces private placement financing up to $50M
Quoin Pharmaceuticals announced private placement financing of up to $50M.
EQUITY | Aug 28, 2026, 11:14 AM UTC
L
Quoin Pharmaceuticals reports positive interim Phase 2/3 data for QRX003
Quoin Pharmaceuticals reported positive interim data from its ongoing Phase 2/3 study of QRX003 in Netherton syndrome.
EQUITY | Aug 28, 2026, 10:07 AM UTC
L
Quoin Pharmaceuticals announces private placement financing up to $50M
Quoin Pharmaceuticals (QNRX) announced a private placement financing of up to $50.0 million.
EQUITY | Aug 28, 2026, 10:00 AM UTC
L
QNRX - Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
QNRX - Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
EQUITY | Aug 28, 2026, 10:00 AM UTC
L
QNRX reports Second Quarter 2026 results and corporate update
Quoin Pharmaceuticals (QNRX) provides a corporate update and reports Second Quarter 2026 financial results.
EARNINGS | Aug 14, 2026, 12:30 PM UTC
L
Quoin Pharmaceuticals Says US FDA Clears Phase 2 Trial of QRX003 in Peeling Skin Syndrome
() -- Quoin Pharmaceuticals (QNRX) said Thursday the US Food and Drug Administration has cleared its planned phase 2 clinical trial of QRX003 to potentially treat peeling skin syndrome. The company said it expects to ini
REGULATION | Jul 09, 2026, 01:42 PM UTC
L
Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application
Quoin Pharmaceuticals announces FDA clearance of QRX003 IND application
EQUITY | Jul 09, 2026, 01:13 PM UTC
L
Quoin Pharmaceuticals Issued Notice Of Allowance From U.S. Patent And Trademark Office Titled Combination Treatment For Netherton Syndrome
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX ) ("Quoin" or the "Company"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that the United States Patent and Tradema
EQUITY | Jun 30, 2026, 12:31 PM UTC
H
Small Caps Surge
Several small cap stocks are experiencing significant gains premarket due to various positive news announcements, including strategic partnerships and favorable trial data.
EQUITY | Jun 24, 2026, 12:21 PM UTC
M
12 Health Care Stocks Move
Twelve health care stocks are moving in Wednesday's pre-market session, with Pulsenmore and Catheter Precision leading the gainers and Nuwellis and Mobile-health Network leading the losers
EQUITY | Jun 24, 2026, 12:09 PM UTC
M
Healthcare Stocks Move
Multiple healthcare stocks are moving in Tuesday's after-market session, with some rising and others falling
EQUITY | Jun 23, 2026, 09:09 PM UTC
H
QNRX Receives FDA Approval
Quoin Pharmaceuticals receives FDA conditional approval of QYLEKI as the proposed brand name for QRX003 for Netherton Syndrome
EQUITY | Jun 23, 2026, 12:30 PM UTC